Speciality Medicines Ltd

Speciality Medicines Limited was originally incorporated as 'Speciality Medicines Private Limited' as a Private Limited Company, dated February 05, 2021, issued by the Registrar of Companies, Central Registration Centre. Later on, the status was converted to Public Limited and the name of the Company was changed to 'Speciality Medicines Limited' and a fresh Certificate of Incorporation dated June 25, 2024 was issued to the Company by Registrar of Companies. The Company is engaged in marketing & distribution of finished formulations of Specialty pharmaceuticals - high-cost oral or injectable medications used to treat complex chronic conditions in Domestic as well as International Market. The Company has presence over 35 countries. The Company deal in Specialty pharmaceuticals finished formulations Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nasal Spray, Ointment, Ophthalmic, Oral Solution, Oral Suspension, Sachet, Suspension and Tablet. It provide a diverse portfolio of specialty pharmaceuticals, focusing on therapeutic areas such as oncology, immunology, neurology, and rare diseases. These products are designed to meet the complex needs of patients with chronic conditions, providing innovative solutions that improve health outcomes. The Company is collaborating with overseas distributors, many of whom work closely with the health ministries of various countries, as well as government and private hospitals. Unlike traditional drugs, which are typically prescribed for common illnesses and follow simpler manufacturing processes, specialty medicines are characterized by their advanced therapeutic properties and the complexity of their development, handling, and administration. Specialty medicines are characterized by their use in treating complex or rare diseases such as cancer, rheumatoid arthritis, multiple sclerosis, haemophilia, and genetic disorders, where standard therapies are often ineffective. They involve advanced technologies like biologics and gene therapies, making their research, development, and manufacturing highly sophisticated and costly, which results in higher prices compared to conventional drugs. These medicines require complex administration and handling, often needing refrigeration, injections, or infusions delivered in clinical settings or through specialty pharmacies. Additionally, they are supported by patient education, adherence programs, and ongoing monitoring to ensure effective treatment outcomes. The Company issued and allotted 23,50,000 Equity Shares of Rs 10 each through IPO on 24 March 2026.